Qiagen N.V.

  • WKN: A2DKCH
  • ISIN: NL0012169213
  • Land: The Netherlands

Nachricht vom 14.08.2018 | 20:00

QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

QIAGEN N.V.

14.08.2018 / 20:00
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The AFM (the Netherlands Authority For the Financial Markets) has informed us on August 11, 2018 that a notification related to our institution has been released by the AFM.

The following notification has been disclosed in the relevant register on the AFM website:

Date of transaction: 8 August 2018
Person obliged to notify: Goldman Sachs Group Inc., The
Issuing institution: Qiagen N.V.
Registration Chamber of Commerce: 12036979
Place of residence: VENLO

Distribution in numbers

Type of share Number of shares Number of voting rights Capital interest Voting rights Manner of disposal Settlement
Ordinary share 494.583,00 494.583,00 Real Real Indirectly - Goldman Sachs Asset Management, L.P. Physical Delivery
Ordinary share 6.023,00 6.023,00 Real Real Indirectly - Goldman Sachs Asset Management International Physical Delivery
Ordinary share 3.012,00 3.012,00 Real Real Indirectly - Goldman Sachs Asset Management Co., Ltd. Physical Delivery
Option 6.900.943,00 6.900.943,00 Potential Potential Indirectly - Goldman Sachs & Co. LLC Physical Delivery
Ordinary share 385.237,00 385.237,00 Potential Potential Indirectly - Goldman Sachs & Co. LLC Physical Delivery
Swap 2.125.042,00 2.125.042,00 Potential Potential Indirectly - Goldman Sachs & Co. LLC In Cash
Convertible bond 1.867.635,00 1.867.635,00 Potential Potential Indirectly - Goldman Sachs International Physical Delivery
 


Distribution in percentages

Type Total holding Directly real Directly potential Indirectly real Indirectly potential
Capital interest 5,10 % 0,00 % 0,00 % 0,22 % 4,89 %
Voting rights 5,10 % 0,00 % 0,00 % 0,22 % 4,89 %
 

QIAGEN N.V. is not responsible for the accuracy and correctness of the notification above. The content has been taken from the relevant register of the AFM:
https://www.afm.nl/en/professionals/registers/meldingenregisters/substantiele-deelnemingen/details?id=61897



14.08.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

UniDevice AG: Rekord-Ergebnis in 2018

Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.

News im Fokus

Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2018

21. Februar 2019, 11:51

Aktueller Webcast

Ströer SE & Co. KGaA

Vorläufige Geschäftszahlen 2018

26. Februar 2019

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

21. Februar 2019